Healthcare provider profile · identity verified

Asya Benin, MD

Internal Medicine · BROOKLYN, NY · NPI 1326111550

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Metoprolol Succinate	Metoprolol Succinate	452	102
Atorvastatin Calcium	Atorvastatin Calcium	395	91
Amlodipine Besylate	Amlodipine Besylate	323	78
Metformin Hcl	Metformin Hcl	263	56
Levothyroxine Sodium	Levothyroxine Sodium	256	46
Losartan Potassium	Losartan Potassium	213	55
Rosuvastatin Calcium	Rosuvastatin Calcium	198	53
Allopurinol	Allopurinol	178	43
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	176	43
Diclofenac Sodium	Diclofenac Sodium	165	34
Vascepa	Icosapent Ethyl	162	26
Gabapentin	Gabapentin	151	36
Synthroid	Levothyroxine Sodium	149	27
Clonidine Hcl	Clonidine Hcl	138	33
Meloxicam	Meloxicam	135	37
Famotidine	Famotidine	131	37
Linzess	Linaclotide	125	26
Furosemide	Furosemide	124	31
Hydralazine Hcl	Hydralazine Hcl	122	29
Hydrochlorothiazide	Hydrochlorothiazide	116	29
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	116	25
Metoprolol Tartrate	Metoprolol Tartrate	112	19
Fluticasone Propionate	Fluticasone Propionate	103	56
Simvastatin	Simvastatin	98	19
Valsartan	Valsartan	96	18
Meclizine Hcl	Meclizine Hcl	90	25
Clopidogrel	Clopidogrel Bisulfate	88	20
Potassium Chloride	Potassium Chloride	88	19
Janumet	Sitagliptin Phos/Metformin Hcl	87	14
Azithromycin	Azithromycin	84	66
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	77	13
Alcohol Prep Pads	Alcohol Antiseptic Pads	75	23
Fenofibrate	Fenofibrate Nanocrystallized	73	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	71	13
Eliquis	Apixaban	70	16
Albuterol Sulfate Hfa	Albuterol Sulfate	61	17
Fenofibrate	Fenofibrate	61	17
Vitamin D2	Ergocalciferol (Vitamin D2)	59	18
Glimepiride	Glimepiride	56	16
Lisinopril	Lisinopril	56	11
Dexlansoprazole Dr	Dexlansoprazole	55	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	54	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	17
Tamsulosin Hcl	Tamsulosin Hcl	54	12
Omeprazole	Omeprazole	48	19
Zenpep	Lipase/Protease/Amylase	48	suppressed
Myrbetriq	Mirabegron	45	suppressed
Citalopram Hbr	Citalopram Hydrobromide	44	suppressed
Celecoxib	Celecoxib	43	suppressed
Creon	Lipase/Protease/Amylase	43	suppressed
Icosapent Ethyl	Icosapent Ethyl	39	suppressed
Atenolol	Atenolol	38	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	37	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	36	suppressed
Carvedilol	Carvedilol	33	suppressed
Ezetimibe	Ezetimibe	31	suppressed
Glipizide Er	Glipizide	31	suppressed
Fluconazole	Fluconazole	30	27
Pantoprazole Sodium	Pantoprazole Sodium	30	suppressed
Febuxostat	Febuxostat	29	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	28	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Nebivolol Hcl	Nebivolol Hcl	27	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Ammonium Lactate	Ammonium Lactate	26	suppressed
Ranolazine Er	Ranolazine	26	suppressed
Single Use Swab	Alcohol Antiseptic Pads	25	suppressed
Acyclovir	Acyclovir	24	suppressed
Mupirocin	Mupirocin	24	12
Nifedipine Er	Nifedipine	24	suppressed
Methimazole	Methimazole	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	21	suppressed
Folic Acid	Folic Acid	21	suppressed
Jardiance	Empagliflozin	20	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	20	16
Labetalol Hcl	Labetalol Hcl	19	suppressed
Montelukast Sodium	Montelukast Sodium	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	17
Entresto	Sacubitril/Valsartan	17	suppressed
Naproxen	Naproxen	17	suppressed
Colchicine	Colchicine	16	suppressed
Finasteride	Finasteride	16	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	16	13
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Levofloxacin	Levofloxacin	15	13
Mirtazapine	Mirtazapine	15	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	14	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Hydrocortisone	Hydrocortisone	13	suppressed
Lubiprostone	Lubiprostone	13	suppressed
Methylprednisolone	Methylprednisolone	13	12
Spironolactone	Spironolactone	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Alcohol Swab	Alcohol Antiseptic Pads	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Pro Comfort Alcohol Pads	Alcohol Antiseptic Pads	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Carbamazepine Er	Carbamazepine	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Potassium Citrate Er	Potassium Citrate	11	suppressed
Repaglinide	Repaglinide	11	suppressed
Ursodiol	Ursodiol	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error